Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASSIST: Atrasentan in IgA Nephropathy on SGLT2i
NCT05834738Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of atrasentan in IgA nephropathy (IgAN), sponsored by Novartis. Started Jul 2023; status: completed.
02
Drugs
atrasentan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT05834738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05834738.